These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495 [TBL] [Abstract][Full Text] [Related]
44. Accuracy of clinical nodal staging and factors associated with receipt of lymph node dissection at the time of surgery for nonmetastatic renal cell carcinoma. Radadia KD; Rivera-Núñez Z; Kim S; Farber NJ; Sterling J; Falkiewicz M; Modi PK; Goyal S; Parikh R; Weiss RE; Kim IY; Elsamra SE; Jang TL; Singer EA Urol Oncol; 2019 Sep; 37(9):577.e17-577.e25. PubMed ID: 31280982 [TBL] [Abstract][Full Text] [Related]
45. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Chapman TN; Sharma S; Zhang S; Wong MK; Kim HL Urology; 2008 Feb; 71(2):287-91. PubMed ID: 18308105 [TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Silagy AW; Flynn J; Mano R; Blum KA; Marcon J; DiNatale RG; Sanchez A; Carlo MI; Motzer RJ; Coleman JA; Russo P; Ostrovnaya I; Chen YB; Hakimi AA Urol Oncol; 2019 Nov; 37(11):811.e9-811.e16. PubMed ID: 31521530 [TBL] [Abstract][Full Text] [Related]
48. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424 [TBL] [Abstract][Full Text] [Related]
49. Influence of lymph node dissection in patients undergoing radical nephrectomy for non-metastatic renal cell carcinoma: a systematic review and meta-analysis. Luo X; Li JX; Liu YT; Zou G; Yao WX; Qing GQ; Yang RL; Ye XY; Facchini G; Rossetti S Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6079-6090. PubMed ID: 31364109 [TBL] [Abstract][Full Text] [Related]
50. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295 [TBL] [Abstract][Full Text] [Related]
51. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease. Blute ML; Amling CL; Bryant SC; Zincke H Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850 [TBL] [Abstract][Full Text] [Related]
52. Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma. Barboza MP; Speir RW; Boris RS; Calaway AC; Cary C; Foster RS; Masterson TA Urol Oncol; 2020 Sep; 38(9):739.e1-739.e8. PubMed ID: 32646691 [TBL] [Abstract][Full Text] [Related]
53. European temporal trends in the use of lymph node dissection in patients with renal cancer. Capitanio U; Stewart GD; Larcher A; Ouzaid I; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Salagierski M; Volpe A; Mir MC; Kriegmair M; Terrone C; Brookman-May SD; Montorsi F; Klatte T; Eur J Surg Oncol; 2017 Nov; 43(11):2184-2192. PubMed ID: 28801061 [TBL] [Abstract][Full Text] [Related]
54. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma. Laba P; Wang J; Zhang J BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799 [TBL] [Abstract][Full Text] [Related]
55. The rationale and the role of lymph node dissection in renal cell carcinoma. Capitanio U; Leibovich BC World J Urol; 2017 Apr; 35(4):497-506. PubMed ID: 27364520 [TBL] [Abstract][Full Text] [Related]
56. Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. Eisenberg MS; Cheville JC; Thompson RH; Kaushik D; Lohse CM; Boorjian SA; Costello BA; Leibovich BC J Urol; 2013 Jul; 190(1):37-43. PubMed ID: 23353044 [TBL] [Abstract][Full Text] [Related]
57. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350 [TBL] [Abstract][Full Text] [Related]
59. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI Urol Oncol; 2020 May; 38(5):537-544. PubMed ID: 32122729 [TBL] [Abstract][Full Text] [Related]
60. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy. Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]